A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study

A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study

Abstract Background Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). The drug is available for Polish patients with IPF since 2017. The PolExPIR study aimed to describe the real-world data (RWD) on the Polish experience of pirfenidone therapy in...

Full description

Bibliographic Details
Main Authors: Sebastian Majewski, Adam J. Białas, Małgorzata Buchczyk, Paweł Gomółka, Katarzyna Górska, Hanna Jagielska-Len, Agnieszka Jarzemska, Ewa Jassem, Dariusz Jastrzębski, Aleksander Kania, Marek Koprowski, Rafał Krenke, Jan Kuś, Katarzyna Lewandowska, Magdalena M. Martusewicz-Boros, Kazimierz Roszkowski-Śliż, Alicja Siemińska, Krzysztof Sładek, Małgorzata Sobiecka, Karolina Szewczyk, Małgorzata Tomczak, Witold Tomkowski, Elżbieta Wiatr, Dariusz Ziora, Beata Żołnowska, Wojciech J. Piotrowski
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Pulmonary Medicine
Subjects:
Pirfenidone
Idiopathic pulmonary fibrosis
Real-world data
Efficacy
Safety
Poland
Online Access:http://link.springer.com/article/10.1186/s12890-020-1162-6

Internet

http://link.springer.com/article/10.1186/s12890-020-1162-6

Similar Items